Eyetronic

Eyetronic’s therapy has proven to halt vision loss (63%) and restore vision (59%). Eyetronic is approved in Europe with more than 1,000 patients treated in 10,000 sessions without a serious adverse event. Their revenue is generated through electronic codes (SaaS). Two clinical trials have started (Stanford, San Francisco) July 2025. Eyetronic’s goal is a US launch in 2028.